ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

A virtual model of a human: science fiction or future? How do we do in silico research?

Los Angeles, California, United States - 01-19-2023 (PR Distribution™) -

Rustam Gilfanov, a Venture Partner at the LongeVC Fund shares his ideas.

Science and medicine develop today at great strides. But is it possible to create a computer model of a human body? Is this something the future holds for us?

In the very beginning of the confluence of medicine and IT technologies, computers were regarded only as an instrument to facilitate the processing of large masses of data. Now science community is thinking of (and working on) holding fully virtual research experiments. A virtual model of a human body would allow medics to create new drugs easier as well as make personalized drugs more available.

How are in silico experiments held?

The first mention of in silico (literally “in silicon”) experiments dates back to the 1990s. Today this term is used almost as often as in vivo (“within the living", i.e., experiments on whole living organisms) and in vitro (“in the glass”, i.e., experiments held in a test-tube artificial environment).

By the in silico experiments we mean putting certain parameters in the computer in order to recreate the results that would be obtained during a real experiment on an analyzed system. At present in silico research also includes predicting the behaviors of certain molecules, biochemical processes, and full physiological systems.

Special attention should be given to in silico modelling of individual molecules. In this case, a computer models the reaction of various molecular systems, for example, amino acid or nucleotide sequences. Not to be forgotten that computers are now indispensable to studying big masses of data (bioinformatics), just as they were in the beginning.

Digital twin startups

Another promising direction of in silico research is the creation of virtual models of individual patients. It gives scientists an opportunity to hold tests with rare phenotypes that are difficult to find for real-life trials. Also, this approach allows for comparing the efficacy of various treatments in a certain patient without spending too much time.

Recently a joint UK and the Netherlands research team under the management of Alejandro F. Frangi (the University of Leeds) successfully proved that a virtual model offered exactly the same results that conventional trials with real patients. The model in question analyzed the treatment of brain aneurysms with a flow-diverting stent applied to a sample of virtual anatomies available in clinical databases. Put more simply, a stent is a tube placed in the artery in order to reduce the blood flow, thus lowering the risks of rupture and ischemic stroke.

Another two projects — The Living Brain and The Living Heart — were created by Dassault Systemes (France) on the 3DExperience platform. After studying available information from patients and various studies, the scientists developed a virtual model of blood circulation that allows them to study different treatments. With the help of the Living Heart, they can create new medical gadgets, test the safety of drugs, and develop personalized surgical treatments.

The other project, Living Brain, helps study epilepsy and determine which parts of the brain are associated with seizures. By 2019 the results of this project were so good that the FDA prolongated its work with Dassault for another five years.

Could we create a full human digital twin?

So far virtual twin technology is only in its infancy. Some of its approaches are used for the creation of new drugs and certain types of personalized therapies. However, the same approaches are already widely applied in other spheres — in the construction, manufacturing, and automobile and aerospace industries. Engineers use them when designing new systems, managing exploitation and calculating possible equipment wear in real time.

Chinese scientists Lui, Zhang, Zhou, together with their colleagues in 2019 formulated the conditions for the creation of a virtual human twin. First, some kind of advanced modeling tool (SysML, Modelica, SolidWorks, 3DMAX, or AutoCAD) should be used. Second, the healthcare Internet of Things (IoT) and mobile connection should be employed for data feed in real time. Third, a model should be subject to routine calibrations. And the last one, the patient should receive the results of any activity applied to his twin model (e.g., diagnostics).

What is now obvious is that the creation of a virtual twin technology would undeniably lead to a medical revolution of our age. Personalized treatments, prevention of diseases and use of patient-specific therapeutic methods based on genetic, biological, phenotypical, physical, and psychosocial peculiarities would become a new medical breakthrough.

Weaknesses of the in silico technology

Currently, the level of technological advancement does not allow us to predict all possible influences of a newly created drug, so for the moment, computer-based research cannot completely take over real-life clinical trials. Thus, unfortunately, the amount of animal tests and time and investment consumption stays the same. Part of the problem is also the lack of trust to computer tests compared to more traditional approaches.

Yes, technological optimists stay very hopeful about the in silico research, but realists consider it very improbable that the technology would ever be able to model all the processes in a living cell. That would literally mean modelling life itself. For many people, this pragmatic approach to life is still something of the blasphemy towards nature.

Let’s assume that one day our technological level would allow us to decipher all the enigmas of the human body. Even with that, we would still need much more progressive methods of data collection and storage, not to mention the cost of medical devices. Until those are available to a wide market, no advancements can be made.

About the author

Written by Rustam Gilfanov, an investor, philanthropist, and a venture partner of the LongeVC fund.

Media Contacts:

Company Name: Blacklight
Full Name: Vlad
Phone: +7 499 340 33 83
Email Address: Send Email
Website: https://blacklight.ru

For the original news story, please visit https://www.prdistribution.com/news/a-virtual-model-of-a-human-science-fiction-or-future-how-do-we-do-in-silico-research/9473590.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.